|MDACC Study No:||2007-0044 (clinicaltrials.gov NCT No: NCT00614653)|
|Title:||Phase I Trial of radiotherapy with concurrent bevacizumab, erlotinib and capecitabine for locally advanced pancreatic cancer|
|Principal Investigator:||Sunil Krishnan|
|Treatment Agent:||Bevacizumab; Capecitabine; Erlotinib; Radiotherapy|
|Study Description:||The goal of this clinical research study is to find the highest tolerable dose |
of capecitabine, erlotinib hydrochloride, and bevacizumab that can be given in
combination with radiation to patients with pancreatic cancer.